Article Text

Download PDFPDF
New oral treatment for atopic dermatitis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Archivist had not heard of JAK. The JAK (Janus kinase) family comprises four molecules (JAK1, JAK2, JAK3, and (strangely) TYK2) and they are essential for intracellular signal transduction via cytokine receptors and crucial to a number of inflammatory pathways. JAK inhibitors can reduce inflammation and three of these inhibitors have now been identified for use in rheumatoid arthritis; tofacitinib, baricitinib and upadacitinib. This drug group have now been used in eczema. Simpson E et al [Lancet 2020; 396: 255–66] have examined abrocitinib, an oral selective Janus kinase one inhibitor in a multicentre, double-blind, randomised phase three trial. There …

View Full Text


  • Provenance and peer review Commissioned; internally peer reviewed.